Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Journal of Gastroenterology|September 17, 2024
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective studyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Anticancer Research|August 28, 2024
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular CarcinomaNobuharu Tamaki, Nami Mori, Shintaro Takaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 7, 2022
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinomaHironori Ochi, Masayuki Kurosaki, Kouji Joko, et al.
Investigational New Drugs|August 30, 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinomaNami Mori, Nobuharu Tamaki, Shintaro Takaki, et al.
Investigational New Drugs|March 30, 2023
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study GroupShintaro Takaki, Masayuki Kurosaki, Nami Mori, et al.
Journal of Viral Hepatitis|May 13, 2022
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study GroupToshie Mashiba, Kouji Joko, Masayuki Kurosaki, et al.
Investigational New Drugs|September 24, 2022
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabNobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 26, 2023
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological responseShun Ishido, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 13, 2025
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective StudyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Cancer Research|October 17, 2020
Hes1 Is Essential in Proliferating Ductal Cell-Mediated Development of Intrahepatic CholangiocarcinomaTomoaki Matsumori, Yuzo Kodama, Atsushi Takai, et al.
Pageof 15